[Mindray Announces Third Quarter 2013 Financial Results Shenzhen, China November4, 2013 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the third quarter ended September30, 2013. Highlights for Third Quarter 2013 Net revenuesreased 15.3% year-over-year to $296.3 million. Internationalles grew]
[Mindray Announces Up to $200 Million Share Repurchase Program Shenzhen, China November4, 2013 Mindray Medical International Limited (Mindray ormpany, NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that its Board of Directors has approved a share repurchase program. The program is authorized to be in effect starting from today]
[Mindray Announces Third Quarter 2013 Financial Results Shenzhen, China November4, 2013 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the third quarter ended September30, 2013. Highlights for Third Quarter 2013 Net revenuesreased 15.3% year-over-year to $296.3 million. Internationalles grew]
[Mindray Announces Second Quarter 2013 Financial Results Shenzhen, China August 5, 2013 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2013. Highlights for Second Quarter 2013 Net revenues increased 14.7% year-over-year to $307.2 million. China]
[Mindray Announces Second Quarter 2013 Financial Results Shenzhen, China August 5, 2013 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June 30, 2013. Highlights for Second Quarter 2013 Net revenues increased 14.7% year-over-year to $307.2 million. China]
[Mindray Announces Second Quarter 2013 Financial Results STYLE="font-family:Times New Roman" SIZE="2">Shenzhen, China August5, 2013 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June30, 2013. Highlights for Second Quarter 2013 Net revenuesreased 14.7% year-over-year to $307.2]
[Mindray Announces Second Quarter 2013 Financial Results STYLE="font-family:Times New Roman" SIZE="2">Shenzhen, China August5, 2013 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June30, 2013. Highlights for Second Quarter 2013 Net revenuesreased 14.7% year-over-year to $307.2]
[Mindray Announces Second Quarter 2013 Financial Results Shenzhen, China August5, 2013 Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the second quarter ended June30, 2013. Highlights for Second Quarter 2013 Net revenuesreased 14.7% year-over-year to $307.2 million. Chinales were]
[Mindray Medical Completes Acquisition of ZONARE Medical Systems Under the agreement, Mindray has acquired ZONARE for a total purchase price of US$101.7 million in cash, as adjusted for working capital at the closing date. The Company expects that the combined business will benefit from ZONAREs strong innovative R&D capability and direct sales and service network in the high-end ultrasound market]
[Mindray Medical Completes Acquisition of ZONARE Medical Systems Under the agreement, Mindray has acquired ZONARE for a total purchase price of US$101.7 million in cash, as adjusted for working capital at the closing date. The Company expects that the combined business will benefit from ZONAREs strong innovative R&D capability and direct sales and service network in the high-end ultrasound market]
